PensiveInvestor
Nov 19, 9:13 PM
$BCTX They doubled the survival to 16.6 months on patients who normally have survival between 6.7 to 9.8 months. The fact that the phase 2 consist of 54 patients, it is not impossible to assume that they can do it in the phase 3 with 177 patients.
Also they don't need to double , they need to improve to 40% in interim analysis or 30% in final analysis. There is a chance, and the longer it takes , the better the odds, similar to
$SLS.
1 replies